Skip to main content
. 2012 Oct 8;7(10):e47049. doi: 10.1371/journal.pone.0047049

Figure 6. AA005 synergizes with 2-DG and cisplatin in colon cancer cells.

Figure 6

(A, B) LOVO cells were treated indicated protocols for 48 h, analyzed by MTT assay (A), and the combined effects were evaluated by the Chou-Talay method and Calcusyn software (B). The combination indexes (CI) less than, equal to, and greater than 1 indicate synergistic, additive, and antagonistic effects, respectively. (C) LOVO cells were treated with 50 nM AA005 or/and 5 mM 2-DG for 24 h, and ATP content was assessed as described above. (D) Western blot analyses of lysates of LOVO cells treated with AA005 or/and 2-DG using indicated antibodies. (E, F) LOVO cells were treated indicated protocols for 48 h, analyzed by MTT assay (E), and the combined effects were evaluated by the Chou-Talay method and Calcusyn software (F). (G) Western blot analyses of lysates of LOVO cells treated with AA005 or/and cisplatin using indicated antibodies. (H) LOVO cells were treated with AA005 and/or cisplatin, and analyzed by Annexin V/PI staining and flow cytometry. (I) The cells were treated with AA005 and/or cisplatin for 24 h, and ATP content was measured using an ATP Bioluminescence Assay Kit. (J) LOVO cells were treated with AA005 and/or cisplatin for 24 h, and cell cycle distribution was determined by flow cytometry.